Comparison · NCT04624633-deaths
Cohort 1 - Relapsed Disease vs Cohort 2 - Treatment Naive: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cohort 1 - Relapsed Disease vs Cohort 2 - Treatment Naive: deaths from any cause. Trial comparisons, record NCT04624633-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04624633-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.125 | 0.0224 | 0.471 | wilson | |
| Risk in group 2 | 0 | 0 | 0.155 | wilson | |
| Risk difference, group 1 minus group 2 | 0.125 | -0.0606 | 0.471 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to harm, for one more death from any cause on Cohort 1 - Relapsed Disease than on Cohort 2 - Treatment Naive | 8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cohort 1 - Relapsed Disease | Participants with relapsed disease~* Treatment with Acalabrutinib \& Umbralisib beginning C1D1,~* Ublituximab beginning C7D1~* Assessment of treatment response~* Treatment continues for a maximum of 24 cycles. Participants followed post treatment for a maximum of 5 years | 1 | 8 | EG000 |
| Group 2 | Cohort 2 - Treatment Naive | Participants with previously untreated disease~* Treatment with Acalabrutinib \& Umbralisib beginning C1D1,~* Ublituximab beginning C7D1~* Assessment of treatment response~* Treatment continues for a maximum of 24 cycles. Participants followed post treatment for a maximum of 5 years | 0 | 21 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
Adverse events (AE) will be evaluated through imaging at cycle 1 day 1, 8, and 15, cycle 2-6 and cycle 8-25 day 1, and cycle 7 day 1, 2 and 8. AE observation on treatment up to approximately 25 cycles.
Source ClinicalTrials.gov
Trial
- Title
- Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
- NCT number
- NCT04624633
- Phases
- PHASE2
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
- Interventions
- Acalabrutinib, Umbralisib, Ublituximab
- Lead sponsor
- Jennifer R. Brown, MD, PhD
- Results first posted
- 2025-02-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04624633?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04624633-deaths